Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRI in advanced esophageal carcinoma
NCT01044420Phase 2Unknown
- Sponsor
- Peking University
- Start
- May 2009
- Primary completion
- Jun 2011
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01044420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01044420.